Janssen Drug Patent Portfolio

Janssen owns 38 orange book drugs protected by 232 US patents with Propulsid Quicksolv having the least patent protection, holding only 1 patent. And Prezista with maximum patent protection, holding 26 patents. and owns 1 purple book drug protected by 6 US patents Given below is the list of Janssen's drug patents along with their expiration dates.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11666697	Methods for ensuring resuspension of paliperidone palmitate formulations	24 Nov, 2041	Active
US11850248	Therapies with 3rd generation EGFR tyrosine kinase inhibitors	01 Aug, 2041	Active
US11304951	Dosing regimens associated with extended release paliperidone injectable formulations	07 May, 2041	Active
US11324751	Dosing regimens associated with extended release paliperidone injectable formulations	07 May, 2041	Active
US12208100	Dosing regimens associated with extended release paliperidone injectable formulations	07 May, 2041	Active
US12138351	Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof	13 Apr, 2041	Active
US11879013	Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors	21 May, 2040	Active
US11883526	Esketamine for the treatment of depression	18 Feb, 2040	Active
US11963952	Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer	30 Jan, 2040	Active
US12303497	Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer	30 Jan, 2040	Active
US10961307	Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody	24 Sep, 2039	Active
US10828310	Reducing the risk of cardiovascular events	31 Jul, 2039	Active
US10828310	Reducing the risk of cardiovascular events	31 Jan, 2039	Active
US10786518	Compositions and methods of treating HIV	19 Jul, 2038	Active
US10702508	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer	30 Apr, 2038	Active
US11453656	Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same	18 Apr, 2038	Active
US11981659	Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same	18 Apr, 2038	Active
US12318390		18 Apr, 2038	Active
US11091459	Niraparib compositions	27 Mar, 2038	Active
US11673877	Niraparib compositions	27 Mar, 2038	Active
US11077106	Cancer treatment	02 Feb, 2038	Active
US11065198	Dispersible compositions	23 Oct, 2037	Active
US11207311	Method of treating prostate cancer	28 Jul, 2037	Active
US11986468	Methods of treating prostate cancer	28 Jul, 2037	Active
US11986469	Methods of treating prostate cancer	28 Jul, 2037	Active
US11992486	Methods of treating prostate cancer	28 Jul, 2037	Active
US12383543		28 Jul, 2037	Active
US10478494	FGFR/PD-1 combination therapy for the treatment of cancer	13 Aug, 2036	Active
US10143693	Dosing regimen for missed doses for long-acting injectable paliperidone esters	05 Apr, 2036	Active
US10898482	Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine	09 Feb, 2036	Active
US11684620	Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine	09 Feb, 2036	Active
US12303493	Anticancer compositions	03 Dec, 2035	Active
US12037644	Use of FGFR mutant gene panels in identifying cancer patients that will be responsive to treatment with an FGFR inhibitor	18 Oct, 2035	Active
US9593098	Compounds and compositions for modulating EGFR mutant kinase activities	13 Oct, 2035	Active
US10869844	Methods for the treatment of depression	10 Sep, 2035	Active
US11173134	Methods for the treatment of depression	10 Sep, 2035	Active
US11311500	Methods for the treatment of depression	10 Sep, 2035	Active
US9902714	Quinoxaline derivatives useful as FGFR kinase modulators	26 Mar, 2035	Active
US10729823		19 Aug, 2034	Active
US12447241		19 Aug, 2034	Active
US9539218	Prevention and treatment of thromboembolic disorders	17 Aug, 2034	Active
US11446260	Pharmaceutical composition of S-ketamine hydrochloride	14 Mar, 2034	Active
US9539218	Prevention and treatment of thromboembolic disorders	17 Feb, 2034	Active
US10052314	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	23 Sep, 2033	Active
US10849888	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	23 Sep, 2033	Active
US9884054	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	23 Sep, 2033	Active
USRE49353	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	23 Sep, 2033	Active
US9481663	Crystalline forms of an androgen receptor modulator	04 Jun, 2033	Active
US8895601	Pyrazolyl quinoxaline kinase inhibitors	12 Apr, 2033	Active
US9217168	Methods of cell culture	14 Mar, 2033	Active
US9663810	Methods of cell culture	14 Mar, 2033	Active
US8785500	Intranasal administration of ketamine to treat depression	05 Mar, 2033	Active
US10039718	Use of solid carrier particles to improve the processability of a pharmaceutical agent	06 Oct, 2032	Active
US8754065	Tenofovir alafenamide hemifumarate	15 Aug, 2032	Active
US9296769	Tenofovir alafenamide hemifumarate	15 Aug, 2032	Active
US8852889	Cell culture process	06 Jul, 2032	Active
US9475858	Cell culture process	06 Jul, 2032	Active
US8679094		15 Apr, 2032	Active
US10617668	Pharmaceutical formulations	11 Nov, 2031	Active
US8859562	Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer	04 Aug, 2031	Active
US10617668	Pharmaceutical formulations	11 May, 2031	Active
US9464071	Pyrazolyl quinoxaline kinase inhibitors	28 Apr, 2031	Active
US8071623	Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors	27 Mar, 2031	Active
US9439906	Dosing regimen associated with long acting injectable paliperidone esters	26 Jan, 2031	Active
US8445507	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases	15 Sep, 2030	Active
US11576894	Combination therapy for the treatment of diabetes	06 Jul, 2030	Active
US12403086		28 Jun, 2030	Active
US8148399	Macrocyclic inhibitors of hepatitis C virus	05 Sep, 2029	Active
US8148374	Modulators of pharmacokinetic properties of therapeutics	03 Sep, 2029	Active
US7943582	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	26 Aug, 2029	Active
US8436185	Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide	24 Apr, 2029	Active
US8546428	Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol	19 Mar, 2029	Active
US7943582	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	26 Feb, 2029	Active
US8895557	Pharmaceutical formulations of ecteinascidin compounds	07 Jul, 2028	Active
US8513202	Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate	03 Jun, 2028	Active
US7943788	Glucopyranoside compound	14 Jan, 2028	Active
US8895557	Pharmaceutical formulations of ecteinascidin compounds	07 Jan, 2028	Active
US8513202	Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate	03 Dec, 2027	Active
US8822438	Methods and compositions for treating cancer	24 Aug, 2027	Active
US8071579	DNA damage repair inhibitors for the treatment of cancer	12 Aug, 2027	Active
US8143241	DNA damage repair inhibitors for treatment of cancer	12 Aug, 2027	Active
US7943788	Glucopyranoside compound	14 Jul, 2027	Active
US7700645	Pseudopolymorphic forms of a HIV protease inhibitor	26 Jun, 2027	Active
US8802689	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases	27 Mar, 2027	Active
US9388159	Substituted diazaspiroalkanes as androgen receptor modulators	27 Mar, 2027	Active
US9987261	Substituted diazaspiroalkanes as androgen receptor modulators	27 Mar, 2027	Active
US9592207	Intranasal administration of ketamine to treat depression	20 Mar, 2027	Active
US7700645	Pseudopolymorphic forms of a HIV protease inhibitor	26 Dec, 2026	Active
US7498343	Mycobacterial inhibitors	01 Dec, 2026	Active
US8349869	Macrocylic inhibitors of hepatitis C virus	28 Jul, 2026	Active
US8741926	Macrocyclic inhibitors of hepatitis C virus	28 Jul, 2026	Active
US8754106	Macrocyclic inhibitors of hepatitis C virus	28 Jul, 2026	Active
US9040562	Macrocyclic inhibitors of hepatitis C virus	28 Jul, 2026	Active
US9353103	Macrocyclic inhibitors of hepatitis C virus	28 Jul, 2026	Active
US9623022	Macrocyclic inhibitors of hepatitis C virus	28 Jul, 2026	Active
US9856265	Macrocyclic inhibitors of hepatitis C virus	28 Jul, 2026	Active
US7125879	HIV inhibiting pyrimidines derivatives	21 Oct, 2025	Expired
US8222219	Glucopyranoside compound	11 Oct, 2025	Expired
US7671032	HCV NS-3 serine protease inhibitors	19 May, 2025	Expired
US9415053	Solid, orally administrable pharmaceutical composition	13 May, 2025	Expired
US7125879	HIV inhibiting pyrimidines derivatives	21 Apr, 2025	Expired
US7390791	Prodrugs of phosphonate nucleotide analogues	17 Apr, 2025	Expired
US8222219	Glucopyranoside compound	11 Apr, 2025	Expired
US7157456	Substituted oxazolidinones and their use in the field of blood coagulation	28 Feb, 2025	Expired
US9415053	Solid, orally administrable pharmaceutical composition	13 Nov, 2024	Expired
US7157456	Substituted oxazolidinones and their use in the field of blood coagulation	28 Aug, 2024	Expired
US8518987	Pseudopolymorphic forms of a HIV protease inhibitor	16 Aug, 2024	Expired
US8785403	Glucopyranoside compound	30 Jul, 2024	Expired
US8518987	Pseudopolymorphic forms of a HIV protease inhibitor	16 Feb, 2024	Expired
US6902734	Anti-IL-12 antibodies and compositions thereof	25 Sep, 2023	Active
US7638522	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile	14 Apr, 2023	Expired
US8080551	HIV inhibiting pyrimidines derivatives	11 Apr, 2023	Expired
US6806256	Taste masked liquid pharmaceutical compositions	26 Aug, 2022	Expired
US8101629	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile	09 Aug, 2022	Expired
US6806256	Taste masked liquid pharmaceutical compositions	26 Feb, 2022	Expired
US7803788	Prodrugs of phosphonate nucoleotide analogues	02 Feb, 2022	Expired
US6723340	Optimal polymer mixtures for gastric retentive tablets	25 Oct, 2021	Expired
US7037917	HIV replication inhibiting pyrimidines	13 Jun, 2021	Expired
US6703396	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers	09 Mar, 2021	Expired
US6838464	2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents	26 Feb, 2021	Expired
US7037917	HIV replication inhibiting pyrimidines	13 Dec, 2020	Expired
US7585860	Substituted oxazolidinones and their use in the field of blood coagulation	11 Dec, 2020	Expired
US7592339	Substituted oxazolidinones and their use in the field of blood coagulation	11 Dec, 2020	Expired
US6667061	Preparation of injectable suspensions having improved injectability	25 Nov, 2020	Expired
US6642245	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane	04 Nov, 2020	Expired
US6667061	Preparation of injectable suspensions having improved injectability	25 May, 2020	Expired
US6878717	HIV replication inhibiting pyrimidines	05 May, 2020	Expired
US8003789	HIV replication inhibiting pyrimidines	01 May, 2020	Expired
US6339105	Analgesic regimen	12 Apr, 2020	Expired
US7470506	Fitness assay and associated methods	23 Dec, 2019	Expired
US8597876	Method of treating HIV infection	23 Dec, 2019	Expired
US9889115	Fitness assay and associated methods	23 Dec, 2019	Expired
US7067522	2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents	20 Dec, 2019	Expired
US7160559	Controlled release galantamine composition	20 Dec, 2019	Expired
US6214815	Triphasic oral contraceptive	09 Dec, 2019	Expired
US6878717	HIV replication inhibiting pyrimidines	05 Nov, 2019	Expired
US8003789	HIV replication inhibiting pyrimidines	01 Nov, 2019	Expired
US6339105	Analgesic regimen	12 Oct, 2019	Expired
US7887845	Antiviral compositions	25 Sep, 2019	Expired
US7125560	Pharmaceutical composition of topiramate	01 Sep, 2019	Expired
US6194006	Preparation of microparticles having a selected release profile	30 Jun, 2019	Expired
US6379703	Preparation of microparticles having a selected release profile	30 Jun, 2019	Expired
US6596316	Preparation of microparticles having a selected release profile	30 Jun, 2019	Expired
US7470506	Fitness assay and associated methods	23 Jun, 2019	Expired
US8597876	Method of treating HIV infection	23 Jun, 2019	Expired
US9889115	Fitness assay and associated methods	23 Jun, 2019	Expired
US6407079	Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation	18 Jun, 2019	Expired
US6214815	Triphasic oral contraceptive	09 Jun, 2019	Expired
US6555544	Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters	10 May, 2019	Expired
US7887845	Antiviral compositions	25 Mar, 2019	Expired
US7125560	Pharmaceutical composition of topiramate	01 Mar, 2019	Expired
US6194006	Preparation of microparticles having a selected release profile	30 Dec, 2018	Expired
US6379703	Preparation of microparticles having a selected release profile	30 Dec, 2018	Expired
US6596316	Preparation of microparticles having a selected release profile	30 Dec, 2018	Expired
US6555544	Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters	10 Nov, 2018	Expired
US6919373	Methods and devices for providing prolonged drug therapy	31 Jan, 2018	Expired
US6930129	Methods and devices for providing prolonged drug therapy	31 Jan, 2018	Expired
US8163798	Methods and devices for providing prolonged drug therapy	31 Jan, 2018	Expired
US8629179	Methods and devices for providing prolonged drug therapy	31 Jan, 2018	Expired
US9000038	Methods and devices for providing prolonged drug therapy	31 Jan, 2018	Expired
US6224905	Biconvex rapidly disintegrating dosage forms	10 Dec, 2017	Expired
US6077843	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters	12 Nov, 2017	Expired
USRE43596	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	09 Nov, 2017	Expired
US5792477	Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent	02 Nov, 2017	Expired
US5916598	Preparation of biodegradable, biocompatible microparticles containing a biologically active agent	02 Nov, 2017	Expired
US6403114	Preparation of biodegradable, biocompatible microparticles containing a biologically active agent	02 Nov, 2017	Expired
US6919373	Methods and devices for providing prolonged drug therapy	31 Jul, 2017	Expired
US6930129	Methods and devices for providing prolonged drug therapy	31 Jul, 2017	Expired
US8163798	Methods and devices for providing prolonged drug therapy	31 Jul, 2017	Expired
US8629179	Methods and devices for providing prolonged drug therapy	31 Jul, 2017	Expired
US9000038	Methods and devices for providing prolonged drug therapy	31 Jul, 2017	Expired
US9029416	Methods and devices for providing prolonged drug therapy	31 Jul, 2017	Expired
US9144549	Methods and devices for providing prolonged drug therapy	31 Jul, 2017	Expired
US6224905	Biconvex rapidly disintegrating dosage forms	10 Jun, 2017	Expired
US6099863	Fast-dissolving galanthamine hydrobromide tablet	06 Jun, 2017	Expired
US6358527	Fast-dissolving galanthamine hydrobromide tablet	06 Jun, 2017	Expired
US6077843	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters	12 May, 2017	Expired
USRE43596	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	09 May, 2017	Expired
US5792477	Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent	02 May, 2017	Expired
US5916598	Preparation of biodegradable, biocompatible microparticles containing a biologically active agent	02 May, 2017	Expired
US6403114	Preparation of biodegradable, biocompatible microparticles containing a biologically active agent	02 May, 2017	Expired
USRE42889	α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	19 Apr, 2017	Expired
USRE43802	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	19 Apr, 2017	Expired
US6037157	Method for improving pharmacokinetics	26 Dec, 2016	Expired
US6703403	Method for improving pharmacokinetics	26 Dec, 2016	Expired
USRE42889	α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	19 Oct, 2016	Expired
USRE43802	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	19 Oct, 2016	Expired
US6037157	Method for improving pharmacokinetics	26 Jun, 2016	Expired
US6703403	Method for improving pharmacokinetics	26 Jun, 2016	Expired
US5843946	α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	01 Jun, 2016	Expired
US5998380	Treatment of migraine	13 Apr, 2016	Expired
US6503884	Migraine treatment method using topiramate and related compounds	13 Apr, 2016	Expired
US7018983	Treatment of migraine	13 Apr, 2016	Expired
US7498311	Treatment of migraine	13 Apr, 2016	Expired
US5843946	α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	01 Dec, 2015	Expired
US5674895	Dosage form comprising oxybutynin	22 Nov, 2015	Expired
US5840754	Dosage form comprising oxybutynin	22 Nov, 2015	Expired
US5912268	Dosage form and method for treating incontinence	22 Nov, 2015	Expired
US6262115	Method for the management of incontinence	22 Nov, 2015	Expired
US5876746	Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen	20 Nov, 2015	Expired
US5565447	Indole derivatives	07 Nov, 2015	Expired
US5998380	Treatment of migraine	13 Oct, 2015	Expired
US6503884	Migraine treatment method using topiramate and related compounds	13 Oct, 2015	Expired
US7018983	Treatment of migraine	13 Oct, 2015	Expired
US7498311	Treatment of migraine	13 Oct, 2015	Expired
US5972377	Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen	07 Jun, 2015	Expired
US5674895	Dosage form comprising oxybutynin	22 May, 2015	Expired
US5840754	Dosage form comprising oxybutynin	22 May, 2015	Expired
US5912268	Dosage form and method for treating incontinence	22 May, 2015	Expired
US6262115	Method for the management of incontinence	22 May, 2015	Expired
US5688801	Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	18 May, 2015	Expired
US5565447	Indole derivatives	07 May, 2015	Expired
US6248775	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	13 Feb, 2015	Expired
US5648093	Pharmaceutical and other dosage forms	15 Jan, 2015	Expired
US5707975	Oral formulations on an antifungal	13 Jan, 2015	Expired
US5453425	Risperidone oral formulation	11 Jan, 2015	Expired
USRE39181	Aqueous risperidone formulations	11 Jan, 2015	Expired
US5688801	Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	18 Nov, 2014	Expired
US6248775	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	13 Aug, 2014	Expired
US5648093	Pharmaceutical and other dosage forms	15 Jul, 2014	Expired
US5453425	Risperidone oral formulation	11 Jul, 2014	Expired
USRE39181	Aqueous risperidone formulations	11 Jul, 2014	Expired
US5633015	Beads having a core coated with an antifungal and a polymer	27 May, 2014	Expired
US5965168	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 May, 2014	Expired
US6110921	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 May, 2014	Expired
US6368632	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 May, 2014	Expired
US7547452	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 May, 2014	Expired
US5254556	3-piperidinyl-1,2-benzisoxazoles	15 Apr, 2014	Expired
US5604213	17-substituted steroids useful in cancer treatment	18 Feb, 2014	Expired
US5965168	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 Nov, 2013	Expired
US6110921	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 Nov, 2013	Expired
US6368632	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 Nov, 2013	Expired
US7547452	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 Nov, 2013	Expired
US5254556	3-piperidinyl-1,2-benzisoxazoles	15 Oct, 2013	Expired
US5352459	Use of purified surface modifiers to prevent particle aggregation during sterilization	16 Jun, 2013	Expired
US6335460	α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors	25 Feb, 2013	Expired
US5352459	Use of purified surface modifiers to prevent particle aggregation during sterilization	16 Dec, 2012	Expired
US6335460	α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors	25 Aug, 2012	Expired

Latest Legal Activities on Janssen's Drug Patents

Given below is the list of recent legal activities going on the following drug patents of Janssen.

Activity	Date	Patent Number

Payment of Maintenance Fee, 4th Year, Large Entity	09 Jul, 2024	US10898482
Payment of Maintenance Fee, 8th Year, Large Entity	26 Jun, 2024	US9539218
Payment of Maintenance Fee, 4th Year, Large Entity	05 Jun, 2024	US10869844
Expire Patent Critical	27 May, 2024	US8163798
Expire Patent Critical	20 May, 2024	US10617668
Payment of Maintenance Fee, 4th Year, Large Entity	15 May, 2024	US10849888
Patent eCofC Notification	30 Apr, 2024	US10702508
Email Notification Critical	30 Apr, 2024	US10702508
Mail Patent eCofC Notification	30 Apr, 2024	US10702508
Recordation of Patent eCertificate of Correction	30 Apr, 2024	US10702508
Payment of Maintenance Fee, 4th Year, Large Entity	24 Apr, 2024	US10828310
Patent Issue Date Used in PTA Calculation Critical	23 Apr, 2024	US11963952
Recordation of Patent eGrant	23 Apr, 2024	US11963952
Patent eGrant Notification	23 Apr, 2024	US11963952
Recordation of Patent Grant Mailed Critical	23 Apr, 2024	US11963952

Janssen's Drug Patent Litigations

Janssen's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 05, 2000, against patent number US6407079. The petitioner , challenged the validity of this patent, with PITHA V. MULLER as the respondent. Click below to track the latest information on how companies are challenging Janssen's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10828310	September, 2022	Final Written Decision - Appealed (28 Jul, 2023)	Bayer Pharma AG et al.	InvaGen Pharmaceuticals, Inc. et al.
US10828310	September, 2022	Final Written Decision - Appealed (28 Jul, 2023)	Bayer Pharma AG et al.	Teva Pharmaceuticals USA, Inc
US10828310	February, 2022	Final Written Decision - Appealed (28 Jul, 2023)	Bayer Pharma AG et al.	Mylan Pharmaceuticals Inc. et al.
US10828310	September, 2022	Final Written Decision (28 Jul, 2023)	Bayer Pharma AG et al.	InvaGen Pharmaceuticals, Inc. et al.
US10828310	September, 2022	Final Written Decision (28 Jul, 2023)	Bayer Pharma AG et al.	Teva Pharmaceuticals USA, Inc
US9439906	February, 2020	Institution Denied (16 Sep, 2020)	Janssen Pharmaceutica NV et al.	Mylan Laboratories Ltd. et al.
US9439906	February, 2020	Terminated-Denied (16 Sep, 2020)	Janssen Pharmaceutica NV	Mylan Laboratories Ltd.
US9539218	May, 2018	Terminated-Denied (03 Dec, 2018)	Bayer Intellectual Property GmbH	Mylan Pharmaceuticals Inc.
US9539218	May, 2018	Institution Denied (03 Dec, 2018)	Bayer Intellectual Property GmbH et al.	Mylan Pharmaceuticals Inc. et al.
US8822438	December, 2015	FWD Entered (17 Jan, 2018)	Janssen Oncology, Inc.	Amerigen Pharmaceuticals, Ltd.
US8822438	June, 2016	Final Written Decision (17 Jan, 2018)	Janssen Oncology, Inc. et al.	Mylan Pharmaceuticals Inc. et al.
US8822438	August, 2016	Final Written Decision (17 Jan, 2018)	Janssen Oncology, Inc. et al.	Wockhardt Bio AG et al.
US8822438	June, 2016	FWD Entered (17 Jan, 2018)	Janssen Oncology, Inc.	Argentum Pharmaceuticals LLC
US8822438	December, 2015	Final Written Decision (17 Jan, 2018)	Janssen Oncology, Inc. et al.	Amerigen Pharmaceuticals, Ltd.
US8822438	February, 2017	Final Written Decision (17 Jan, 2018)	Janssen Oncology, Inc. et al.	ACTAVIS LABORATORIES FL, INC. et al.
US8822438	June, 2016	FWD Entered (17 Jan, 2018)	Janssen Oncology, Inc.	Mylan Pharmaceuticals Inc.
US8822438	February, 2017	FWD Entered (17 Jan, 2018)	Janssen Oncology, Inc.	ACTAVIS LABORATORIES FL, INC.
US8822438	June, 2016	Final Written Decision (17 Jan, 2018)	Janssen Oncology, Inc. et al.	Argentum Pharmaceuticals LLC et al.
US8822438	August, 2016	FWD Entered (17 Jan, 2018)	Janssen Oncology, Inc.	Wockhardt Bio AG
US6667061	May, 2016	Final Written Decision (28 Nov, 2017)	Alkermes Controlled Therapeutics, Inc. et al.	Luye Pharma Group Ltd. et al.
US6667061	May, 2016	FWD Entered (28 Nov, 2017)	Alkermes Controlled Therapeutics, Inc.	Luye Pharma Group Ltd.
US7157456	October, 2016	Terminated (29 Mar, 2017)	Bayer Intellectual Property GmbH et al.	Mylan Pharmaceuticals Inc et al.
US7592339	October, 2016	Terminated (29 Mar, 2017)	Bayer Intellectual Property GmbH et al.	Mylan Pharmaceuticals Inc. et al.
US7585860	October, 2016	Terminated (29 Mar, 2017)	Bayer Intellectual Property GmbH et al.	Mylan Pharmaceuticals Inc. et al.
US6667061	May, 2016	Institution Denied (30 Nov, 2016)	Alkermes Controlled Therapeutics, Inc. et al.	Luye Pharma Group Ltd. et al.
US6667061	May, 2016	Terminated-Denied (30 Nov, 2016)	Alkermes Controlled Therapeutics, Inc.	Luye Pharma Group Ltd.
US9539218	January, 2014	Decision (01 Jun, 2016)	Frank Misselwitz et al
US8518987	April, 2015	Terminated-Denied (16 Oct, 2015)	Janssen Sciences Ireland UC	Lupin Limited
US8518987	April, 2015	Institution Denied (16 Oct, 2015)	Janssen Sciences Ireland UC	Lupin Limited et al.
US6723340	April, 2014	Final Written Decision (16 Sep, 2015)	DepoMed, Inc.	Endo Pharmaceutical Inc. et al.
US6723340	April, 2014	Institution Denied (29 Sep, 2014)	DepoMed, Inc.	Endo Pharmaceutical Inc. et al.
US8859562	October, 2011	Decision (25 Mar, 2014)	Thomas Helleday
US6703396	April, 2002	Decision (04 Apr, 2002)	DIONNE
US6642245	July, 2001	Decision (05 Jul, 2001)	DIONNE
US6407079	October, 2000	Decision (05 Oct, 2000)	PITHA V. MULLER

Janssen Drug Patents' Oppositions Filed in EPO

Janssen drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 12, 2008, by Ratiopharm Gmbh. This opposition was filed on patent number EP04797879A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status

EP19169275A	Feb, 2022	Generics [UK] Limited	Granted and Under Opposition
EP08863534A	Dec, 2021	Zentiva k.s.	Granted and Under Opposition
EP08863534A	Dec, 2021	EGIS Gyógyszergyár Zártkörüen Müködö Részvénytársaság	Granted and Under Opposition
EP08863534A	Dec, 2021	Hoffmann Eitle SLU	Granted and Under Opposition
EP08863534A	Dec, 2021	Gill Jennings & Every LLP	Granted and Under Opposition
EP08863534A	Dec, 2021	Farmaprojects S.A.U.	Granted and Under Opposition
EP08863534A	Dec, 2021	Laboratorios Lesvi, S.L.	Granted and Under Opposition
EP08863534A	Dec, 2021	Sun Pharmaceutical Industries Europe B.V.	Granted and Under Opposition
EP08863534A	Dec, 2021	Tolmar International Limited	Granted and Under Opposition
EP08863534A	Dec, 2021	BIOGARAN	Granted and Under Opposition
EP08863534A	Dec, 2021	df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB	Granted and Under Opposition
EP08863534A	Dec, 2021	Accord Healthcare Ltd	Granted and Under Opposition
EP08863534A	Dec, 2021	Hoffmann Eitle	Granted and Under Opposition
EP08863534A	Dec, 2021	EVER Valinject GmbH	Granted and Under Opposition
EP08863534A	Dec, 2021	Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi	Granted and Under Opposition
EP08863534A	Dec, 2021	Maiwald Patent- und Rechtsanwaltsgesellschaft mbH	Granted and Under Opposition
EP08863534A	Dec, 2021	Abbott Products Operations AG	Granted and Under Opposition
EP08863534A	Dec, 2021	Stada-Arzneimittel Aktiengesellschaft	Granted and Under Opposition
EP08863534A	Dec, 2021	Instone, Terry/Appleyard Lees IP LLP/Read, Howard	Granted and Under Opposition
EP08863534A	Dec, 2021	Advanz Pharma Services (UK) Ltd.	Granted and Under Opposition
EP17187458A	Jun, 2021	Sandoz AG	Granted and Under Opposition
EP17187458A	Jun, 2021	Synthon BV	Granted and Under Opposition
EP17187458A	Jun, 2021	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP06706291A	Apr, 2021	Krka, d.d., Novo mesto	Opposition rejected
EP18157435A	Apr, 2021	Sagittarius Intellectual Property Consultants Ltd	Granted and Under Opposition
EP18157435A	Apr, 2021	SANDOZ AG	Granted and Under Opposition
EP08863534A	Mar, 2021	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP06706291A	Mar, 2021	Zentiva Group, a.s.	Opposition rejected
EP16777058A	Jan, 2021	STADA Arzneimittel AG	Granted and Under Opposition
EP16777058A	Jan, 2021	df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB	Granted and Under Opposition
EP16777058A	Jan, 2021	Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB	Granted and Under Opposition
EP16777058A	Jan, 2021	Hexal AG	Granted and Under Opposition
EP16777058A	Jan, 2021	Accord Healthcare Ltd	Granted and Under Opposition
EP16777058A	Jan, 2021	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP16777058A	Jan, 2021	Hamm&Wittkopp Patentanwälte PartmbB	Granted and Under Opposition
EP16777058A	Dec, 2020	Instone, Terry/Read, Howard Graham/Appleyard Lees IP LLP	Granted and Under Opposition
EP16180589A	Oct, 2020	Cooke, Richard	Granted and Under Opposition
EP16180589A	Oct, 2020	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP10735109A	Jan, 2020	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP10735109A	Jan, 2020	Generics [UK] Limited	Granted and Under Opposition
EP16180589A	Jan, 2020	STADA Arzneimittel AG	Granted and Under Opposition
EP13800681A	Jan, 2019	Generics (U.K.) Limited	Granted and Under Opposition
EP13800681A	Jan, 2019	Luigi, Rumi	Granted and Under Opposition
EP13800681A	Jan, 2019	Sagittarius Intellectual Property LLP	Granted and Under Opposition
EP14194507A	Jun, 2018	Galenicum Health S.L.	Patent maintained as amended
EP14194507A	Jun, 2018	Generics (UK) Ltd	Patent maintained as amended
EP14168686A	Apr, 2018	Cooke, Richard	Opposition rejected
EP13164300A	Jan, 2018	Georg Kalhammer/Stephan Teipel	Granted and Under Opposition
EP13164300A	Jan, 2018	Cooke, Richard	Granted and Under Opposition
EP13164300A	Jan, 2018	Aechter, Bernd	Granted and Under Opposition
EP12753867A	Jul, 2017	FRKelly	Granted and Under Opposition
EP12753867A	Jul, 2017	Sandoz GmbH	Granted and Under Opposition
EP12753867A	Jul, 2017	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP12167591A	May, 2017	Cooke, Richard	Revoked
EP12167590A	May, 2017	Cooke, Richard	Revoked
EP12167590A	May, 2017	Teva Pharmaceutical Industries LTD.	Revoked
EP12167591A	May, 2017	Teva Pharmaceutical Industries LTD.	Revoked
EP12167589A	May, 2017	Cooke, Richard	Granted and Under Opposition
EP12167589A	May, 2017	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP12167596A	Apr, 2017	Cooke, Richard	Revoked
EP12167596A	Apr, 2017	Teva Pharmaceutical Industries Ltd	Revoked
EP11721616A	Apr, 2017	LEK Pharmaceuticals d.d.	Revoked
EP09739981A	Jun, 2016	Cooke, Richard	Revoked
EP09739981A	Jun, 2016	Teva Pharmaceutical Industries Ltd	Revoked
EP10703766A	Apr, 2016	Cooke, Richard	Revoked
EP10703766A	Apr, 2016	Teva Pharmaceutical Industries Ltd	Revoked
EP07836007A	Mar, 2016	Trösch, Dominique	Granted and Under Opposition
EP07836007A	Mar, 2016	Georg Kalhammer/Stephan Teipel	Granted and Under Opposition
EP07836007A	Mar, 2016	Teva Pharmaceutical Industries LTD.	Granted and Under Opposition
EP06706291A	Jan, 2016	ABG Patentes, S.L.	Opposition rejected
EP06706291A	Jan, 2016	Hexal AG	Opposition rejected
EP06706291A	Jan, 2016	Kraus & Weisert Patentanwälte PartGmbB	Opposition rejected
EP06706291A	Jan, 2016	Galenicum Health S.L.	Opposition rejected
EP04787096A	Jan, 2016	Page White & Farrer Limited	Patent maintained as amended
EP06706291A	Jan, 2016	Stolmár, Matthias	Opposition rejected
EP06706291A	Jan, 2016	STADA Arzneimittel AG	Opposition rejected
EP06706291A	Jan, 2016	Generics [UK] Limited (trading as Mylan)	Opposition rejected
EP06706291A	Jan, 2016	Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi	Opposition rejected
EP06706291A	Jan, 2016	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Opposition rejected
EP06706291A	Jan, 2016	Wittkopp, Alexander	Opposition rejected
EP06706291A	Jan, 2016	Teva Pharmaceutical Industries Ltd.	Opposition rejected
EP06706291A	Jan, 2016	Actavis Group PTC ehf	Opposition rejected
EP01961695A	Nov, 2015	HEXAL PHARMA AG	Patent maintained as amended
EP01961695A	Nov, 2015	Strawman Limited	Patent maintained as amended
EP01961695A	Nov, 2015	Swindell & Pearson Limited	Patent maintained as amended
EP01961695A	Nov, 2015	Teva Pharmaceutical Industries Ltd	Patent maintained as amended
EP06706291A	Jul, 2015	Breuer, Markus	Opposition rejected
EP10180831A	Mar, 2015	Wittkopp, Alexander	Patent maintained as amended
EP03753571A	Mar, 2015	Wittkopp, Alexander	Patent maintained as amended
EP10180831A	Mar, 2015	Strawman Limited	Patent maintained as amended
EP03753571A	Mar, 2015	Strawman Limited	Patent maintained as amended
EP10180831A	Mar, 2015	Alfred E. Tiefenbacher (GmbH & Co. KG)	Patent maintained as amended
EP03753571A	Mar, 2015	Alfred E. Tiefenbacher (GmbH & Co. KG)	Patent maintained as amended
EP07850306A	Nov, 2014	Galenicum Health S.L.	Patent maintained as amended
EP04771314A	Oct, 2013	Galenicum Health S.L.	Patent maintained as amended
EP07847697A	Feb, 2013	Gallafent, Antony Xavier	Opposition rejected
EP04798705A	May, 2012	Adams, Harvey Vaughan John	Opposition procedure closed
EP04798705A	May, 2012	STRAWMAN LIMITED	Opposition procedure closed
EP04743564A	Apr, 2012	Adams, Harvey Vaughan John	Patent maintained as amended
EP04743564A	Apr, 2012	STRAWMAN LIMITED	Patent maintained as amended
EP05108086A	Feb, 2012	Hamm, Volker	The patent has been limited
EP2006000431W	Jan, 2012	Spanolux N.V.- DIV. Balterio	Opposition rejected
EP04797879A	Nov, 2008	Ratiopharm GmbH	Patent maintained as amended

Janssen's Family Patents

Janssen drugs have patent protection in a total of 71 countries. It's US patent count contributes only to 14.1% of its total global patent coverage. 12 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Janssen Drug List

Given below is the complete list of Janssen's drugs and the patents protecting them.

1. Akeega

Akeega is protected by 12 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11091459	Niraparib compositions	27 Mar, 2038 (12 years from now)	Active
US11673877	Niraparib compositions	27 Mar, 2038 (12 years from now)	Active
US11207311	Method of treating prostate cancer	28 Jul, 2037 (11 years from now)	Active
US11986468	Methods of treating prostate cancer	28 Jul, 2037 (11 years from now)	Active
US11986469	Methods of treating prostate cancer	28 Jul, 2037 (11 years from now)	Active
US11992486	Methods of treating prostate cancer	28 Jul, 2037 (11 years from now)	Active
US12383543		28 Jul, 2037 (11 years from now)	Active
US8859562	Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer	04 Aug, 2031 (5 years from now)	Active
US8071623	Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors	27 Mar, 2031 (5 years from now)	Active
US8436185	Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide	24 Apr, 2029 (3 years from now)	Active
US8071579	DNA damage repair inhibitors for the treatment of cancer	12 Aug, 2027 (1 year, 7 months from now)	Active
US8143241	DNA damage repair inhibitors for treatment of cancer	12 Aug, 2027 (1 year, 7 months from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Akeega's drug page

2. Axert

Axert is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5565447 (Pediatric)	Indole derivatives	07 Nov, 2015 (10 years ago)	Expired
US5565447	Indole derivatives	07 May, 2015 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Axert's drug page

3. Balversa

Balversa is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11077106	Cancer treatment	02 Feb, 2038 (12 years from now)	Active
US10478494	FGFR/PD-1 combination therapy for the treatment of cancer	13 Aug, 2036 (10 years from now)	Active
US10898482	Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine	09 Feb, 2036 (10 years from now)	Active
US11684620	Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine	09 Feb, 2036 (10 years from now)	Active
US12037644	Use of FGFR mutant gene panels in identifying cancer patients that will be responsive to treatment with an FGFR inhibitor	18 Oct, 2035 (9 years from now)	Active
US9902714	Quinoxaline derivatives useful as FGFR kinase modulators	26 Mar, 2035 (9 years from now)	Active
US8895601	Pyrazolyl quinoxaline kinase inhibitors	12 Apr, 2033 (7 years from now)	Active
US9464071	Pyrazolyl quinoxaline kinase inhibitors	28 Apr, 2031 (5 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Balversa's drug page

4. Concerta

Concerta is protected by 12 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6919373 (Pediatric)	Methods and devices for providing prolonged drug therapy	31 Jan, 2018 (7 years ago)	Expired
US6930129 (Pediatric)	Methods and devices for providing prolonged drug therapy	31 Jan, 2018 (7 years ago)	Expired
US8163798 (Pediatric)	Methods and devices for providing prolonged drug therapy	31 Jan, 2018 (7 years ago)	Expired
US8629179 (Pediatric)	Methods and devices for providing prolonged drug therapy	31 Jan, 2018 (7 years ago)	Expired
US9000038 (Pediatric)	Methods and devices for providing prolonged drug therapy	31 Jan, 2018 (7 years ago)	Expired
US6919373	Methods and devices for providing prolonged drug therapy	31 Jul, 2017 (8 years ago)	Expired
US6930129	Methods and devices for providing prolonged drug therapy	31 Jul, 2017 (8 years ago)	Expired
US8163798	Methods and devices for providing prolonged drug therapy	31 Jul, 2017 (8 years ago)	Expired
US8629179	Methods and devices for providing prolonged drug therapy	31 Jul, 2017 (8 years ago)	Expired
US9000038	Methods and devices for providing prolonged drug therapy	31 Jul, 2017 (8 years ago)	Expired
US9029416	Methods and devices for providing prolonged drug therapy	31 Jul, 2017 (8 years ago)	Expired
US9144549	Methods and devices for providing prolonged drug therapy	31 Jul, 2017 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Concerta's drug page

5. Ditropan Xl

Ditropan Xl is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5674895 (Pediatric)	Dosage form comprising oxybutynin	22 Nov, 2015 (10 years ago)	Expired
US5840754 (Pediatric)	Dosage form comprising oxybutynin	22 Nov, 2015 (10 years ago)	Expired
US5912268 (Pediatric)	Dosage form and method for treating incontinence	22 Nov, 2015 (10 years ago)	Expired
US6262115 (Pediatric)	Method for the management of incontinence	22 Nov, 2015 (10 years ago)	Expired
US5674895	Dosage form comprising oxybutynin	22 May, 2015 (10 years ago)	Expired
US5840754	Dosage form comprising oxybutynin	22 May, 2015 (10 years ago)	Expired
US5912268	Dosage form and method for treating incontinence	22 May, 2015 (10 years ago)	Expired
US6262115	Method for the management of incontinence	22 May, 2015 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ditropan Xl's drug page

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

6. Edurant

Edurant is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7125879 (Pediatric)	HIV inhibiting pyrimidines derivatives	21 Oct, 2025 (2 months ago)	Expired
US7125879	HIV inhibiting pyrimidines derivatives	21 Apr, 2025 (8 months ago)	Expired
US7638522	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile	14 Apr, 2023 (2 years ago)	Expired
US8080551	HIV inhibiting pyrimidines derivatives	11 Apr, 2023 (2 years ago)	Expired
US8101629	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile	09 Aug, 2022 (3 years ago)	Expired
US6838464	2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents	26 Feb, 2021 (4 years ago)	Expired
US7067522	2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents	20 Dec, 2019 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Edurant's drug page

7. Edurant Ped

Edurant Ped is protected by 2 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11065198	Dispersible compositions	23 Oct, 2037 (11 years from now)	Active
US7125879	HIV inhibiting pyrimidines derivatives	21 Apr, 2025 (8 months ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Edurant Ped's drug page

8. Erleada

Erleada is protected by 13 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11963952	Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer	30 Jan, 2040 (14 years from now)	Active
US12303497	Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer	30 Jan, 2040 (14 years from now)	Active
US10702508	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer	30 Apr, 2038 (12 years from now)	Active
US12303493	Anticancer compositions	03 Dec, 2035 (9 years from now)	Active
US10052314	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	23 Sep, 2033 (7 years from now)	Active
US10849888	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	23 Sep, 2033 (7 years from now)	Active
US9884054	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	23 Sep, 2033 (7 years from now)	Active
USRE49353	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	23 Sep, 2033 (7 years from now)	Active
US9481663	Crystalline forms of an androgen receptor modulator	04 Jun, 2033 (7 years from now)	Active
US8445507	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases	15 Sep, 2030 (4 years from now)	Active
US8802689	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases	27 Mar, 2027 (1 year, 2 months from now)	Active
US9388159	Substituted diazaspiroalkanes as androgen receptor modulators	27 Mar, 2027 (1 year, 2 months from now)	Active
US9987261	Substituted diazaspiroalkanes as androgen receptor modulators	27 Mar, 2027 (1 year, 2 months from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Erleada's drug page

9. Inlexzo

Inlexzo is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Expiry	Status
US10729823	19 Aug, 2034 (8 years from now)	Active
US12447241	19 Aug, 2034 (8 years from now)	Active
US8679094	15 Apr, 2032 (6 years from now)	Active
US12403086	28 Jun, 2030 (4 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Inlexzo's drug page

10. Intelence

Intelence is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7037917 (Pediatric)	HIV replication inhibiting pyrimidines	13 Jun, 2021 (4 years ago)	Expired
US7037917	HIV replication inhibiting pyrimidines	13 Dec, 2020 (5 years ago)	Expired
US6878717 (Pediatric)	HIV replication inhibiting pyrimidines	05 May, 2020 (5 years ago)	Expired
US8003789 (Pediatric)	HIV replication inhibiting pyrimidines	01 May, 2020 (5 years ago)	Expired
US6878717	HIV replication inhibiting pyrimidines	05 Nov, 2019 (6 years ago)	Expired
US8003789	HIV replication inhibiting pyrimidines	01 Nov, 2019 (6 years ago)	Expired
US7887845 (Pediatric)	Antiviral compositions	25 Sep, 2019 (6 years ago)	Expired
US7887845	Antiviral compositions	25 Mar, 2019 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Intelence's drug page

11. Invega Hafyera

Invega Hafyera is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11666697	Methods for ensuring resuspension of paliperidone palmitate formulations	24 Nov, 2041 (15 years from now)	Active
US11304951	Dosing regimens associated with extended release paliperidone injectable formulations	07 May, 2041 (15 years from now)	Active
US11324751	Dosing regimens associated with extended release paliperidone injectable formulations	07 May, 2041 (15 years from now)	Active
US12208100	Dosing regimens associated with extended release paliperidone injectable formulations	07 May, 2041 (15 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invega Hafyera's drug page

12. Invega Sustenna

Invega Sustenna is protected by 9 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9439906	Dosing regimen associated with long acting injectable paliperidone esters	26 Jan, 2031 (5 years from now)	Active
US6555544 (Pediatric)	Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters	10 May, 2019 (6 years ago)	Expired
US6555544	Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters	10 Nov, 2018 (7 years ago)	Expired
US6077843 (Pediatric)	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters	12 Nov, 2017 (8 years ago)	Expired
US6077843	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters	12 May, 2017 (8 years ago)	Expired
US5254556 (Pediatric)	3-piperidinyl-1,2-benzisoxazoles	15 Apr, 2014 (11 years ago)	Expired
US5254556	3-piperidinyl-1,2-benzisoxazoles	15 Oct, 2013 (12 years ago)	Expired
US5352459 (Pediatric)	Use of purified surface modifiers to prevent particle aggregation during sterilization	16 Jun, 2013 (12 years ago)	Expired
US5352459	Use of purified surface modifiers to prevent particle aggregation during sterilization	16 Dec, 2012 (13 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invega Sustenna's drug page

13. Invega Trinza

Invega Trinza is protected by 3 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10143693	Dosing regimen for missed doses for long-acting injectable paliperidone esters	05 Apr, 2036 (10 years from now)	Active
US6077843 (Pediatric)	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters	12 Nov, 2017 (8 years ago)	Expired
US6077843	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters	12 May, 2017 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invega Trinza's drug page

14. Invokamet

Invokamet is protected by 10 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11576894	Combination therapy for the treatment of diabetes	06 Jul, 2030 (4 years from now)	Active
US7943582 (Pediatric)	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	26 Aug, 2029 (3 years from now)	Active
US7943582	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	26 Feb, 2029 (3 years from now)	Active
US8513202 (Pediatric)	Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate	03 Jun, 2028 (2 years from now)	Active
US7943788 (Pediatric)	Glucopyranoside compound	14 Jan, 2028 (2 years from now)	Active
US8513202	Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate	03 Dec, 2027 (1 year, 10 months from now)	Active
US7943788	Glucopyranoside compound	14 Jul, 2027 (1 year, 6 months from now)	Active
US8222219 (Pediatric)	Glucopyranoside compound	11 Oct, 2025 (2 months ago)	Expired
US8222219	Glucopyranoside compound	11 Apr, 2025 (8 months ago)	Expired
US8785403	Glucopyranoside compound	30 Jul, 2024 (1 year, 5 months ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invokamet's drug page

15. Invokamet Xr

Invokamet Xr is protected by 10 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7943582 (Pediatric)	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	26 Aug, 2029 (3 years from now)	Active
US7943582	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	26 Feb, 2029 (3 years from now)	Active
US8513202 (Pediatric)	Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate	03 Jun, 2028 (2 years from now)	Active
US7943788 (Pediatric)	Glucopyranoside compound	14 Jan, 2028 (2 years from now)	Active
US8513202	Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate	03 Dec, 2027 (1 year, 10 months from now)	Active
US7943788	Glucopyranoside compound	14 Jul, 2027 (1 year, 6 months from now)	Active
US8222219 (Pediatric)	Glucopyranoside compound	11 Oct, 2025 (2 months ago)	Expired
US8222219	Glucopyranoside compound	11 Apr, 2025 (8 months ago)	Expired
US8785403	Glucopyranoside compound	30 Jul, 2024 (1 year, 5 months ago)	Expired
US6723340	Optimal polymer mixtures for gastric retentive tablets	25 Oct, 2021 (4 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invokamet Xr's drug page

16. Invokana

Invokana is protected by 10 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10617668 (Pediatric)	Pharmaceutical formulations	11 Nov, 2031 (5 years from now)	Active
US10617668	Pharmaceutical formulations	11 May, 2031 (5 years from now)	Active
US7943582 (Pediatric)	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	26 Aug, 2029 (3 years from now)	Active
US7943582	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	26 Feb, 2029 (3 years from now)	Active
US8513202 (Pediatric)	Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate	03 Jun, 2028 (2 years from now)	Active
US7943788 (Pediatric)	Glucopyranoside compound	14 Jan, 2028 (2 years from now)	Active
US8513202	Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate	03 Dec, 2027 (1 year, 10 months from now)	Active
US7943788	Glucopyranoside compound	14 Jul, 2027 (1 year, 6 months from now)	Active
US8222219 (Pediatric)	Glucopyranoside compound	11 Oct, 2025 (2 months ago)	Expired
US8222219	Glucopyranoside compound	11 Apr, 2025 (8 months ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invokana's drug page

17. Lazcluze

Lazcluze is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11850248	Therapies with 3rd generation EGFR tyrosine kinase inhibitors	01 Aug, 2041 (15 years from now)	Active
US12138351	Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof	13 Apr, 2041 (15 years from now)	Active
US11879013	Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors	21 May, 2040 (14 years from now)	Active
US11453656	Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same	18 Apr, 2038 (12 years from now)	Active
US11981659	Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same	18 Apr, 2038 (12 years from now)	Active
US12318390		18 Apr, 2038 (12 years from now)	Active
US9593098	Compounds and compositions for modulating EGFR mutant kinase activities	13 Oct, 2035 (9 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lazcluze's drug page

18. Levaquin

Levaquin is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6806256 (Pediatric)	Taste masked liquid pharmaceutical compositions	26 Aug, 2022 (3 years ago)	Expired
US6806256	Taste masked liquid pharmaceutical compositions	26 Feb, 2022 (3 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levaquin's drug page

19. Olysio

Olysio is protected by 9 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8148399	Macrocyclic inhibitors of hepatitis C virus	05 Sep, 2029 (3 years from now)	Active
US8349869	Macrocylic inhibitors of hepatitis C virus	28 Jul, 2026 (6 months from now)	Active
US8741926	Macrocyclic inhibitors of hepatitis C virus	28 Jul, 2026 (6 months from now)	Active
US8754106	Macrocyclic inhibitors of hepatitis C virus	28 Jul, 2026 (6 months from now)	Active
US9040562	Macrocyclic inhibitors of hepatitis C virus	28 Jul, 2026 (6 months from now)	Active
US9353103	Macrocyclic inhibitors of hepatitis C virus	28 Jul, 2026 (6 months from now)	Active
US9623022	Macrocyclic inhibitors of hepatitis C virus	28 Jul, 2026 (6 months from now)	Active
US9856265	Macrocyclic inhibitors of hepatitis C virus	28 Jul, 2026 (6 months from now)	Active
US7671032	HCV NS-3 serine protease inhibitors	19 May, 2025 (7 months ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Olysio's drug page

20. Ortho Evra

Ortho Evra is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5876746	Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen	20 Nov, 2015 (10 years ago)	Expired
US5972377	Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen	07 Jun, 2015 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ortho Evra's drug page

21. Ortho Tri-cyclen Lo

Ortho Tri-cyclen Lo is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6214815 (Pediatric)	Triphasic oral contraceptive	09 Dec, 2019 (6 years ago)	Expired
US6214815	Triphasic oral contraceptive	09 Jun, 2019 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ortho Tri-cyclen Lo's drug page

22. Prezcobix

Prezcobix is protected by 19 patents, out of which 15 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10039718	Use of solid carrier particles to improve the processability of a pharmaceutical agent	06 Oct, 2032 (6 years from now)	Active
US8148374	Modulators of pharmacokinetic properties of therapeutics	03 Sep, 2029 (3 years from now)	Active
US7700645 (Pediatric)	Pseudopolymorphic forms of a HIV protease inhibitor	26 Jun, 2027 (1 year, 5 months from now)	Active
US7700645	Pseudopolymorphic forms of a HIV protease inhibitor	26 Dec, 2026 (11 months from now)	Active
US8518987 (Pediatric)	Pseudopolymorphic forms of a HIV protease inhibitor	16 Aug, 2024 (1 year, 4 months ago)	Expired
US8518987	Pseudopolymorphic forms of a HIV protease inhibitor	16 Feb, 2024 (1 year, 10 months ago)	Expired
US7470506 (Pediatric)	Fitness assay and associated methods	23 Dec, 2019 (6 years ago)	Expired
US8597876 (Pediatric)	Method of treating HIV infection	23 Dec, 2019 (6 years ago)	Expired
US7470506	Fitness assay and associated methods	23 Jun, 2019 (6 years ago)	Expired
US8597876	Method of treating HIV infection	23 Jun, 2019 (6 years ago)	Expired
US9889115	Fitness assay and associated methods	23 Jun, 2019 (6 years ago)	Expired
USRE43596 (Pediatric)	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	09 Nov, 2017 (8 years ago)	Expired
USRE43596	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	09 May, 2017 (8 years ago)	Expired
USRE42889 (Pediatric)	α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	19 Apr, 2017 (8 years ago)	Expired
USRE43802 (Pediatric)	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	19 Apr, 2017 (8 years ago)	Expired
USRE42889	α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	19 Oct, 2016 (9 years ago)	Expired
USRE43802	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	19 Oct, 2016 (9 years ago)	Expired
US5843946 (Pediatric)	α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	01 Jun, 2016 (9 years ago)	Expired
US5843946	α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	01 Dec, 2015 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prezcobix's drug page

23. Prezista

Prezista is protected by 26 patents, out of which 24 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7700645 (Pediatric)	Pseudopolymorphic forms of a HIV protease inhibitor	26 Jun, 2027 (1 year, 5 months from now)	Active
US7700645	Pseudopolymorphic forms of a HIV protease inhibitor	26 Dec, 2026 (11 months from now)	Active
US8518987 (Pediatric)	Pseudopolymorphic forms of a HIV protease inhibitor	16 Aug, 2024 (1 year, 4 months ago)	Expired
US8518987	Pseudopolymorphic forms of a HIV protease inhibitor	16 Feb, 2024 (1 year, 10 months ago)	Expired
US7470506 (Pediatric)	Fitness assay and associated methods	23 Dec, 2019 (6 years ago)	Expired
US8597876 (Pediatric)	Method of treating HIV infection	23 Dec, 2019 (6 years ago)	Expired
US9889115 (Pediatric)	Fitness assay and associated methods	23 Dec, 2019 (6 years ago)	Expired
US7470506	Fitness assay and associated methods	23 Jun, 2019 (6 years ago)	Expired
US8597876	Method of treating HIV infection	23 Jun, 2019 (6 years ago)	Expired
US9889115	Fitness assay and associated methods	23 Jun, 2019 (6 years ago)	Expired
USRE43596 (Pediatric)	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	09 Nov, 2017 (8 years ago)	Expired
USRE43596	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	09 May, 2017 (8 years ago)	Expired
USRE42889 (Pediatric)	α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	19 Apr, 2017 (8 years ago)	Expired
USRE43802 (Pediatric)	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	19 Apr, 2017 (8 years ago)	Expired
US6037157 (Pediatric)	Method for improving pharmacokinetics	26 Dec, 2016 (9 years ago)	Expired
US6703403 (Pediatric)	Method for improving pharmacokinetics	26 Dec, 2016 (9 years ago)	Expired
USRE42889	α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	19 Oct, 2016 (9 years ago)	Expired
USRE43802	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	19 Oct, 2016 (9 years ago)	Expired
US6037157	Method for improving pharmacokinetics	26 Jun, 2016 (9 years ago)	Expired
US6703403	Method for improving pharmacokinetics	26 Jun, 2016 (9 years ago)	Expired
US5843946 (Pediatric)	α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	01 Jun, 2016 (9 years ago)	Expired
US5843946	α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	01 Dec, 2015 (10 years ago)	Expired
US6248775 (Pediatric)	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	13 Feb, 2015 (10 years ago)	Expired
US6248775	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	13 Aug, 2014 (11 years ago)	Expired
US6335460 (Pediatric)	α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors	25 Feb, 2013 (12 years ago)	Expired
US6335460	α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors	25 Aug, 2012 (13 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prezista's drug page

24. Propulsid Quicksolv

Propulsid Quicksolv is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5648093	Pharmaceutical and other dosage forms	15 Jul, 2014 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Propulsid Quicksolv's drug page

25. Razadyne

Razadyne is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6099863	Fast-dissolving galanthamine hydrobromide tablet	06 Jun, 2017 (8 years ago)	Expired
US6358527	Fast-dissolving galanthamine hydrobromide tablet	06 Jun, 2017 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Razadyne's drug page

26. Razadyne Er

Razadyne Er is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7160559	Controlled release galantamine composition	20 Dec, 2019 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Razadyne Er's drug page

27. Risperdal

Risperdal is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6224905 (Pediatric)	Biconvex rapidly disintegrating dosage forms	10 Dec, 2017 (8 years ago)	Expired
US6224905	Biconvex rapidly disintegrating dosage forms	10 Jun, 2017 (8 years ago)	Expired
US5648093 (Pediatric)	Pharmaceutical and other dosage forms	15 Jan, 2015 (10 years ago)	Expired
US5453425 (Pediatric)	Risperidone oral formulation	11 Jan, 2015 (11 years ago)	Expired
USRE39181 (Pediatric)	Aqueous risperidone formulations	11 Jan, 2015 (11 years ago)	Expired
US5648093	Pharmaceutical and other dosage forms	15 Jul, 2014 (11 years ago)	Expired
US5453425	Risperidone oral formulation	11 Jul, 2014 (11 years ago)	Expired
USRE39181	Aqueous risperidone formulations	11 Jul, 2014 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Risperdal's drug page

28. Risperdal Consta

Risperdal Consta is protected by 24 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6667061 (Pediatric)	Preparation of injectable suspensions having improved injectability	25 Nov, 2020 (5 years ago)	Expired
US6667061	Preparation of injectable suspensions having improved injectability	25 May, 2020 (5 years ago)	Expired
US6194006 (Pediatric)	Preparation of microparticles having a selected release profile	30 Jun, 2019 (6 years ago)	Expired
US6379703 (Pediatric)	Preparation of microparticles having a selected release profile	30 Jun, 2019 (6 years ago)	Expired
US6596316 (Pediatric)	Preparation of microparticles having a selected release profile	30 Jun, 2019 (6 years ago)	Expired
US6194006	Preparation of microparticles having a selected release profile	30 Dec, 2018 (7 years ago)	Expired
US6379703	Preparation of microparticles having a selected release profile	30 Dec, 2018 (7 years ago)	Expired
US6596316	Preparation of microparticles having a selected release profile	30 Dec, 2018 (7 years ago)	Expired
US5792477 (Pediatric)	Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent	02 Nov, 2017 (8 years ago)	Expired
US5916598 (Pediatric)	Preparation of biodegradable, biocompatible microparticles containing a biologically active agent	02 Nov, 2017 (8 years ago)	Expired
US6403114 (Pediatric)	Preparation of biodegradable, biocompatible microparticles containing a biologically active agent	02 Nov, 2017 (8 years ago)	Expired
US5792477	Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent	02 May, 2017 (8 years ago)	Expired
US5916598	Preparation of biodegradable, biocompatible microparticles containing a biologically active agent	02 May, 2017 (8 years ago)	Expired
US6403114	Preparation of biodegradable, biocompatible microparticles containing a biologically active agent	02 May, 2017 (8 years ago)	Expired
US5688801 (Pediatric)	Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	18 May, 2015 (10 years ago)	Expired
US5688801	Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	18 Nov, 2014 (11 years ago)	Expired
US5965168 (Pediatric)	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 May, 2014 (11 years ago)	Expired
US6110921 (Pediatric)	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 May, 2014 (11 years ago)	Expired
US6368632 (Pediatric)	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 May, 2014 (11 years ago)	Expired
US7547452 (Pediatric)	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 May, 2014 (11 years ago)	Expired
US5965168	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 Nov, 2013 (12 years ago)	Expired
US6110921	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 Nov, 2013 (12 years ago)	Expired
US6368632	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 Nov, 2013 (12 years ago)	Expired
US7547452	Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles	19 Nov, 2013 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Risperdal Consta's drug page

29. Sirturo

Sirturo is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8546428	Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol	19 Mar, 2029 (3 years from now)	Active
US7498343	Mycobacterial inhibitors	01 Dec, 2026 (10 months from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sirturo's drug page

30. Sporanox

Sporanox is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6407079	Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation	18 Jun, 2019 (6 years ago)	Expired
US5707975	Oral formulations on an antifungal	13 Jan, 2015 (10 years ago)	Expired
US5633015	Beads having a core coated with an antifungal and a polymer	27 May, 2014 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sporanox's drug page

31. Spravato

Spravato is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11883526	Esketamine for the treatment of depression	18 Feb, 2040 (14 years from now)	Active
US10869844	Methods for the treatment of depression	10 Sep, 2035 (9 years from now)	Active
US11173134	Methods for the treatment of depression	10 Sep, 2035 (9 years from now)	Active
US11311500	Methods for the treatment of depression	10 Sep, 2035 (9 years from now)	Active
US11446260	Pharmaceutical composition of S-ketamine hydrochloride	14 Mar, 2034 (8 years from now)	Active
US8785500	Intranasal administration of ketamine to treat depression	05 Mar, 2033 (7 years from now)	Active
US9592207	Intranasal administration of ketamine to treat depression	20 Mar, 2027 (1 year, 2 months from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Spravato's drug page

32. Symtuza

Symtuza is protected by 14 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10786518	Compositions and methods of treating HIV	19 Jul, 2038 (12 years from now)	Active
US10039718	Use of solid carrier particles to improve the processability of a pharmaceutical agent	06 Oct, 2032 (6 years from now)	Active
US8754065	Tenofovir alafenamide hemifumarate	15 Aug, 2032 (6 years from now)	Active
US9296769	Tenofovir alafenamide hemifumarate	15 Aug, 2032 (6 years from now)	Active
US8148374	Modulators of pharmacokinetic properties of therapeutics	03 Sep, 2029 (3 years from now)	Active
US7700645	Pseudopolymorphic forms of a HIV protease inhibitor	26 Dec, 2026 (11 months from now)	Active
US7390791	Prodrugs of phosphonate nucleotide analogues	17 Apr, 2025 (8 months ago)	Expired
US8518987	Pseudopolymorphic forms of a HIV protease inhibitor	16 Feb, 2024 (1 year, 10 months ago)	Expired
US7803788	Prodrugs of phosphonate nucoleotide analogues	02 Feb, 2022 (3 years ago)	Expired
US6703396	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers	09 Mar, 2021 (4 years ago)	Expired
US6642245	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane	04 Nov, 2020 (5 years ago)	Expired
US7470506	Fitness assay and associated methods	23 Jun, 2019 (6 years ago)	Expired
US8597876	Method of treating HIV infection	23 Jun, 2019 (6 years ago)	Expired
US9889115	Fitness assay and associated methods	23 Jun, 2019 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symtuza's drug page

33. Topamax

Topamax is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7125560 (Pediatric)	Pharmaceutical composition of topiramate	01 Sep, 2019 (6 years ago)	Expired
US7125560	Pharmaceutical composition of topiramate	01 Mar, 2019 (6 years ago)	Expired
US5998380 (Pediatric)	Treatment of migraine	13 Apr, 2016 (9 years ago)	Expired
US6503884 (Pediatric)	Migraine treatment method using topiramate and related compounds	13 Apr, 2016 (9 years ago)	Expired
US7018983 (Pediatric)	Treatment of migraine	13 Apr, 2016 (9 years ago)	Expired
US7498311 (Pediatric)	Treatment of migraine	13 Apr, 2016 (9 years ago)	Expired
US5998380	Treatment of migraine	13 Oct, 2015 (10 years ago)	Expired
US6503884	Migraine treatment method using topiramate and related compounds	13 Oct, 2015 (10 years ago)	Expired
US7018983	Treatment of migraine	13 Oct, 2015 (10 years ago)	Expired
US7498311	Treatment of migraine	13 Oct, 2015 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Topamax's drug page

34. Topamax Sprinkle

Topamax Sprinkle is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7125560 (Pediatric)	Pharmaceutical composition of topiramate	01 Sep, 2019 (6 years ago)	Expired
US7125560	Pharmaceutical composition of topiramate	01 Mar, 2019 (6 years ago)	Expired
US5998380 (Pediatric)	Treatment of migraine	13 Apr, 2016 (9 years ago)	Expired
US6503884 (Pediatric)	Migraine treatment method using topiramate and related compounds	13 Apr, 2016 (9 years ago)	Expired
US7018983 (Pediatric)	Treatment of migraine	13 Apr, 2016 (9 years ago)	Expired
US7498311 (Pediatric)	Treatment of migraine	13 Apr, 2016 (9 years ago)	Expired
US5998380	Treatment of migraine	13 Oct, 2015 (10 years ago)	Expired
US6503884	Migraine treatment method using topiramate and related compounds	13 Oct, 2015 (10 years ago)	Expired
US7018983	Treatment of migraine	13 Oct, 2015 (10 years ago)	Expired
US7498311	Treatment of migraine	13 Oct, 2015 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Topamax Sprinkle's drug page

35. Ultram

Ultram is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6339105 (Pediatric)	Analgesic regimen	12 Apr, 2020 (5 years ago)	Expired
US6339105	Analgesic regimen	12 Oct, 2019 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ultram's drug page

36. Xarelto

Xarelto is protected by 10 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10828310 (Pediatric)	Reducing the risk of cardiovascular events	31 Jul, 2039 (13 years from now)	Active
US10828310	Reducing the risk of cardiovascular events	31 Jan, 2039 (13 years from now)	Active
US9539218 (Pediatric)	Prevention and treatment of thromboembolic disorders	17 Aug, 2034 (8 years from now)	Active
US9539218	Prevention and treatment of thromboembolic disorders	17 Feb, 2034 (8 years from now)	Active
US9415053 (Pediatric)	Solid, orally administrable pharmaceutical composition	13 May, 2025 (7 months ago)	Expired
US7157456 (Pediatric)	Substituted oxazolidinones and their use in the field of blood coagulation	28 Feb, 2025 (10 months ago)	Expired
US9415053	Solid, orally administrable pharmaceutical composition	13 Nov, 2024 (1 year, 1 month ago)	Expired
US7157456	Substituted oxazolidinones and their use in the field of blood coagulation	28 Aug, 2024 (1 year, 4 months ago)	Expired
US7585860	Substituted oxazolidinones and their use in the field of blood coagulation	11 Dec, 2020 (5 years ago)	Expired
US7592339	Substituted oxazolidinones and their use in the field of blood coagulation	11 Dec, 2020 (5 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xarelto's drug page

37. Yondelis

Yondelis is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8895557 (Pediatric)	Pharmaceutical formulations of ecteinascidin compounds	07 Jul, 2028 (2 years from now)	Active
US8895557	Pharmaceutical formulations of ecteinascidin compounds	07 Jan, 2028 (1 year, 11 months from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yondelis's drug page

38. Zytiga

Zytiga is protected by 2 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8822438	Methods and compositions for treating cancer	24 Aug, 2027 (1 year, 7 months from now)	Active
US5604213	17-substituted steroids useful in cancer treatment	18 Feb, 2014 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zytiga's drug page

39. Stelara

Stelara is protected by 6 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10961307	Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody	24 Sep, 2039 (13 years from now)	Active
US9217168	Methods of cell culture	14 Mar, 2033 (7 years from now)	Active
US9663810	Methods of cell culture	14 Mar, 2033 (7 years from now)	Active
US8852889	Cell culture process	06 Jul, 2032 (6 years from now)	Active
US9475858	Cell culture process	06 Jul, 2032 (6 years from now)	Active
US6902734	Anti-IL-12 antibodies and compositions thereof	25 Sep, 2023 (2 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Stelara's drug page

Pharsight

Pharsight

Latest Legal Activities on Janssen's Drug Patents

Janssen's Drug Patent Litigations

Janssen Drug Patents' Oppositions Filed in EPO

Janssen's Family Patents

Janssen Drug List

Explore Our Curated Drug Screens

Related content

Have Questions?